Kelsey Baker

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome

Moreno Festuccia, H. Joachim Deeg, Theodore A. Gooley et al. · Biology of Blood and Marrow Transplantation · 2016 · 48 citations · Full text

Medicine, Hematology, Hematologic Oncology +16

Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft-versus-Host Disease

Jane Turner, Qianchuan He, Kelsey Baker et al. · Transplantation and Cellular Therapy · 2021 · 37 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents

Moreno Festuccia, Kelsey Baker, Theodore A. Gooley et al. · Biology of Blood and Marrow Transplantation · 2017 · 36 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

<i>KRAS</i>Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas

Adam Diehl, Lindsay M. Hannan, David B. Zhen et al. · The Oncologist · 2022 · 32 citations · Full text

Medicine, Genetics, Oncology +17

A Phase I Trial of First-in-Human Alpha-Emitter Astatine-211-Labeled Anti-CD45 Antibody (211At-BC8-B10) in Combination with Fludarabine and TBI As Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS): Preliminary Results of Dose Escalation

Brenda M. Sandmaier, D. Scott Wilbur, Donald K. Hamlin et al. · Transplantation and Cellular Therapy · 2021 · 12 citations · Full text

Medicine, Hematology, Oncology +17